Daratumumab and hyaluronidase-fihj (subcutaneous route)

Darzalex Faspro

Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, lenalidomide, and dexamethasone to treat newly diagnosed multiple myeloma (a type of bone marrow cancer) in patients who can receive autologous stem cell transplant (transplant that uses their own stem cells). Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, melphalan, and prednisone to treat newly diagnosed multiple myeloma in patients who cannot receive autologous stem cell transplant. Daratumumab and hyaluronidase-fihj combination injection is used together with lenalidomide and dexamethasone to treat newly diagnosed multiple myeloma in patients who cannot receive autologous stem cell transplant. It is also used together with lenalidomide and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received at least 1 previous treatment. Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib, thalidomide, and dexamethasone to treat newly diagnosed multiple myeloma who can receive autologous stem cell transplant. Daratumumab and hyaluronidase-fihj combination injection is used together with bortezomib and dexamethasone to treat multiple myeloma in patients who have received at least 1 previous treatment. Daratumumab and hyaluronidase-fihj combination injection is used together with pomalidomide and dexamethasone to treat multiple myeloma in patients who have received at least 1 previous treatment (eg, lenalidomide and a proteasome inhibitor). Daratumumab and hyaluronidase-fihj combination injection is also used together with carfilzomib and dexamethasone to treat relapsed (cancer that has come back) or refractory (cancer that did not respond to treatment) multiple myeloma in patients who have received 1 to 3 previous treatment. Daratumumab and hyaluronidase-fihj combination injection is also used alone to treat multiple myeloma in patients who have received at least 3 previous treatments or in patients who did not respond to previous treatments. These previous treatments include a proteasome inhibitor and an immunomodulatory agent. Daratumumab and hyaluronidase-fihj combination injection is also used together with bortezomib, cyclophosphamide, and dexamethasone to treat newly diagnosed light chain amyloidosis. This medicine is to be given only by or under the supervision of your doctor. This product is available in the following dosage forms:

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered: Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully. Appropriate studies have not been performed on the relationship of age to the effects of daratumumab and hyaluronidase-fihj combination injection in the pediatric population. Safety and efficacy have not been established. Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of daratumumab and hyaluronidase-fihj combination injection in the elderly. However, elderly patients are more likely to have unwanted side effects which may require caution in patients receiving this medicine. There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding. Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine. Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco. The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially: